A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
GD Borasio, W Robberecht, PN Leigh, J Emile… - Neurology, 1998 - AAN Enterprises
GD Borasio, W Robberecht, PN Leigh, J Emile, RJ Guiloff, F Jerusalem, V Silani, PE Vos…
Neurology, 1998•AAN EnterprisesTo test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in
ALS, 183 patients from eight European centers were randomized to receive double-blind
placebo (n= 59) or rhIGF-I 0.1 mg/kg/day (n= 124) subcutaneously for 9 months. At study
completion, the primary efficacy outcome measure (change in disease progression as
assessed by the Appel ALS rating scale) showed no significant difference between
treatment groups. RhIGF-I appeared to be safe and well-tolerated.
ALS, 183 patients from eight European centers were randomized to receive double-blind
placebo (n= 59) or rhIGF-I 0.1 mg/kg/day (n= 124) subcutaneously for 9 months. At study
completion, the primary efficacy outcome measure (change in disease progression as
assessed by the Appel ALS rating scale) showed no significant difference between
treatment groups. RhIGF-I appeared to be safe and well-tolerated.
To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.
American Academy of Neurology